Squamous cell carcinoma of the head and neck region: Insights from the American Society of clinical oncology 2008 presentations

Indian Journal of Cancer

Volumn 45, Issue 3, 2008, Pages 90-92

  Desai, C ^a  

^a Vedanta Institute of Medical Sciences   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HEAD AND NECK TUMOR; HEALTH CARE ORGANIZATION; HUMAN; INDIA; REVIEW; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; INDIA; SOCIETIES, SCIENTIFIC;

EID: 57349092130     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.44062     Document Type: Review

References (11)

1. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
2. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006;24:1072-8.
3. Gillham C. Toxicity of cetuximab and radiotherapy in locally advanced head and neck cancer: a community-based experience. J Clin Oncol; 26:6020.
4. Mesia R. Safety report of a randomized phase II trial to evaluate the combination of cetuximab plus accelerated concomitant boost radiotherapy (RT) followed or not followed by cetuximab monotherapy in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx. J Clin Oncol; 26:6076.
5. Langer CJ. Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol; 26:6006.
6. Kuhnt T. Concomitant hyperfractionated accelerated radiotherapy (HART) with cisplatin and concurrent cetuximab for locoregionally advanced squamous cell head and neck cancer: a phase I dose escalation trial. J Clin Oncol; 26:6029.
7. Vermorken JB, Remenar E, van Herpen C, Gorila T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704.
8. Bonnin N. Efficacy of neoadjuvant TPF (nTPF; docetaxel, T; cisplatin, P; 5FU) in nonselected patients (pts) with head and neck cancer and subsequent radiotherapy (RT) combined with chemotherapy (CT) or cetuximab (Cx). J Clin Oncol; 26:6074.
9. Argiris AE. Phase II trial of neoadjuvant docetaxel (T), cisplatin (P), and cetuximab (E) followed by concurrent radiation (X), P, and E In locally advanced head and neck cancer (HNC). J Clin Oncol; 26:6002.
10. Knoedler M. Phase II trial to evaluate efficacy and toxicity of cetuximab plus docetaxel in platinum pretreated patients with recurrent and/or metastatic head and neck cancer. J Clin Oncol; 26:6066
11. Tra F, Fesen M, Nisty R. Albuterol-based premedication therapy for the prevention of cetuximab infusion-related reactions. J Clin Oncol; 26:17040.